Palm Melanie D
Art of Skin MD, 437 S. Highway 101, Suite 217, Solana Beach, California 92075, USA.
Semin Cutan Med Surg. 2014 Dec;33(4):157-63. doi: 10.12788/j.sder.0116.
The amount of fillers approved by the United States Food and Drug Administration (FDA) for use in facial volume augmentation is diminutive in comparison to filler products employed worldwide. In the near future, several new hyaluronic acid filler products will be available to the United States market. Already approved fillers include Belotero Balance for fine lines, Juvéderm Voluma XC for midfacial volume loss replacement, and Restylane Silk for perioral lines and lip augmentation. Volbella, currently under FDA evaluation, will be used for fine-line correction and lip augmentation. The physiochemical properties, best practices, clinical uses, and side effects of these fillers are discussed. Additionally, evolving techniques such as the use of blunt-tipped microcannulas are explained.
与全球使用的填充剂产品相比，美国食品药品监督管理局（FDA）批准用于面部容积增大的填充剂数量很少。在不久的将来，几种新型透明质酸填充剂产品将在美国市场上市。已获批的填充剂包括用于治疗细纹的贝洛特罗平衡（Belotero Balance）、用于中面部容积缺失替代的乔雅登极致（Juvéderm Voluma XC）以及用于口周纹和丰唇的瑞蓝丝柔（Restylane Silk）。目前正在接受FDA评估的沃尔贝拉（Volbella）将用于细纹矫正和丰唇。本文讨论了这些填充剂的物理化学性质、最佳操作方法、临床用途及副作用。此外，还解释了诸如使用钝头微套管等不断发展的技术。
